Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EIPT intensified pharmacological treatment vs treatment as usual after first-line failure
2022-502185-24-00Phase 3Withdrawn
- Sponsor
- University Medical Center Utrecht
- Start
- Jun 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised trial of esketamine, clozapine and quetiapine in schizophrenia, schizoaffective disorder, schizophreniform disorder and 2 more (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Change in symptom severity total score. Planned start Jun 2023; status: withdrawn.
02
Drugs
esketamineclozapinequetiapine
03
Conditions
schizophreniaschizoaffective disorderschizophreniform disordermajor depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on 2022-502185-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502185-24-00.